PAYRETAILERS
3.2.2023 09:01:36 CET | Business Wire | Press release
PayRetailers, LATAM’s leading all-in-one payment technology provider, has announced today the appointment of Lorenzo Pellegrino as Chief Operating & Digital Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230203005003/en/
Lorenzo Pellegrino, Chief Operating & Digital Officer (Photo: PayRetailers)
Pellegrino comes to PayRetailers at a time of rapid growth, as it has expanded from seven to 11 offices, more than doubled headcount to over 200, and acquired Paygol in Chile and Pago Digital in Colombia. He will lead the deployment of PayRetailers’ resources, working to enhance the company’s technology offering and international platform – to support the merchant community, and the way it can access and move funds quickly and safely.
Payment industry leader
Pellegrino is a highly respected payments industry leader with almost 20 years of senior management experience. Most recently he was CEO of Skrill and NETELLER, heading their digital wallets businesses, alongside leading the marketing affiliate services company, Income Access – all part of the Paysafe Group Plc. While there, he coordinated efforts to drive Paysafe’s 2021 IPO on the New York Stock Exchange (NYSE).
Between 2012 and 2015, Pellegrino was also Executive Vice President for Digital Development for Optimal Payments Plc, leading their go-to-market strategy of the NETELLER wallet business and acquisition of Skrill. He spearheaded the company’s effort in integrating both wallet businesses which led to significant operational efficiencies and margin optimization. Before joining Optimal Payments, he held various executive level positions at Skrill (previously known as Moneybookers) and led their business development efforts in the US.
Lorenzo Pellegrino, COO & CDO, commented: “I’m thrilled to have joined a fast-growing business with so much potential. PayRetailers has a great business model and talented management team that will capitalize on the evolving payments landscape. Innovation and collaboration among our teams will lead us to great achievements and I am impressed by the team’s ability to deliver quality new products at speed.
“There are tremendous opportunities ahead and together we will seek to deliver greater value for our customers as we scale the business. Having been CEO in my previous role, I have a deep appreciation of what it takes to bring a business like PayRetailers to the next level of growth. I look forward to working with the board and leadership team as we usher in PayRetailers’ next chapter of growth and success, and I thank them for their warm welcome.”
Juan Pablo Jutgla, CEO & Founder of PayRetailers, commented: “In Lorenzo, we have chosen a leader uniquely positioned to execute and evolve PayRetailers’ strategy while continuing to generate growth. He has earned a reputation as a strong business leader with immense sector knowledge and has an excellent track record of leading businesses in both developed and emerging markets.
“We believe his strong leadership experience will help focus PayRetailers to become the payment method of choice to increase our community of merchants. We are delighted he will be supporting the company into a bright future and are excited as we enter the next chapter in PayRetailers’ journey.”
For more information about PayRetailers, please visit the company's website at https://payretailers.com.
About PayRetailers
Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offer global merchants more than 250 payment methods without the need of a local entity.
PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions.
PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay and Peru.
Website: https://www.payretailers.com
LinkedIn: https://www.linkedin.com/company/pay-retailers/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230203005003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom